阿尔茨海默氏症进展中的炎症酶: Nrf2作为预防性点
Rubén López-Hernández1, María Magdalena de la Torre-Álamo2, Belén García-Bueno2
1Molecular Inflammation Group, Pathophysiology of the Inflammation and Oxidative Stress Lab, Biomedical Research Institute of Murcia (IMIB), University Clinical Hospital Virgen de la Arrixaca, 30120 Murcia, Spain.
Antioxidants (Basel, Switzerland)
|February 26, 2025
概括
阿尔茨海默病涉及像NLRP3这样的炎症体,由粉样质斑块和陶团被激活. 针对NLRP3和促进Nrf2提供了一种减少神经炎症和对抗阿尔茨海默氏症病理学的策略.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 病理学 病理学 病理学
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样斑块 (Aβ1-42) 和陶,导致神经元损失.
- 神经炎症是由微质激活和炎症媒介驱动的,对阿尔茨海默病的进展有显著的贡献.
- 炎症酶,特别是NLRP3,越来越多地被认为是它们在AD病变发生中的作用,促进细胞因子释放和热.
研究的目的:
- 审查当前对阿尔茨海默病炎症组参与的理解.
- 探索针对AD中神经炎症的治疗策略.
- 突出Nrf2作为AD治疗点的潜力.
主要方法:
- 关于阿尔茨海默病,神经炎症,炎症体 (NLRP3,ASC) 和 Nrf2 的研究的文献综述.
- 对将Aβ1-42和Tau病理与炎症酶激活联系起来的机制的分析.
- 检查自清除缺陷与炎症细胞积累的关系.
主要成果:
- Aβ1-42和高酸化的Tau激活NLRP3炎症体,加剧神经炎症.
- ASC斑点的形成加速了Aβ聚合,并维持了炎症.
- 炎症细胞的缺陷自清除有助于AD的慢性炎症.
结论:
- 抑制NLRP3炎症酶激活和促进ASC斑点降解是对AD的潜在治疗途径.
- 转录因子Nrf2由于其抗炎和抗氧化特性,对阿尔茨海默氏症的治疗有希望.
- 通过Nrf2调制准炎酶驱动的神经炎症可能为阿尔茨海默病提供一种新的治疗策略.
相关概念视频
02:26NF-κB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
02:26NF-kB-dependent Signaling Pathway
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...